<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01053962</url>
  </required_header>
  <id_info>
    <org_study_id>SP-SP304201-09</org_study_id>
    <nct_id>NCT01053962</nct_id>
  </id_info>
  <brief_title>SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation</brief_title>
  <acronym>CIC</acronym>
  <official_title>A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 14-Day Repeat, Oral, Dose Ranging Study to Assess the Safety, Pharmacokinetic and Pharmacodynamic Effects of SP-304 in Patients With Chronic Idiopathic Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch Health Americas, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2a, randomized, double-blind, placebo-controlled, 14-day repeat oral, dose
      ranging study to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD)
      effects of SP-304 in patients with chronic idiopathic constipation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2a, randomized, double-blind, placebo-controlled, 14-day repeat oral, dose
      ranging study to determine the safety, PK and PD effects of SP-304 in patients with chronic
      idiopathic constipation. Patients diagnosed with chronic idiopathic constipation (CIC) will
      be screened for the anticipated 4 cohorts, to yield 80 randomized patients for enrollment.
      Four dose cohorts are planned (0.3 mg, 1.0 mg, 3.0mg, and 9.0 mg) with 20 patients per dose
      cohort [randomization ratio 3:1 (15 receive SP-304:5 receive placebo)]. Patients who continue
      to meet all the entry criteria and complete the pre-treatment bowel movement (BM) diary will
      receive, in a double-blind, randomized fashion, SP-304 or matching placebo. It is expected
      that each patient will complete all 14 days of dosing (including making accurate BM diary
      entries for all 14 days in the treatment period). All patients receiving at least one dose of
      SP-304 or matching placebo will be considered evaluable for the safety endpoints. If a
      patient receives at least 5 doses per treatment week (1 dose per day for 7 days) and has
      completed BM diary entries for those 5 dosing days in each corresponding treatment week,
      he/she will be considered evaluable.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>21 days: Baseline through Follow-up (Treatment Days 14, 7 days post treatment)</time_frame>
    <description>Incidences of adverse events from Baseline through the end of the Follow-up period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Overall in Number of Complete Spontaneous Bowel Movements (CSBM)</measure>
    <time_frame>Study days 1 through 14</time_frame>
    <description>Using a Daily Diary, patients recorded the number of spontaneous bowel movements having the sensation of complete evacuation (Complete Spontaneous Bowel Movement - CSBM). The total number of spontaneous bowel movements associated with a feeling of complete evacuation were summed and divided by 2 (the number of weeks in treatment). Change was calculated as the difference between the number of the CSBMs at the completion of the 2-week treatment period, versus the 14-day pretreatment baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Overall in Number of Spontaneous Bowel Movements (SBM)</measure>
    <time_frame>Study Days 1 through 14</time_frame>
    <description>Using a Daily Diary, patients recorded the number of spontaneous bowel movements (SBM). The overall weekly frequency was calculated as the total number of SBMs divided by 2 (the number weeks of treatment). Change was calculated as the difference between the number of the SBMs at the completion of the 2-week treatment period, versus the 14-day pretreatment baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline Overall in Bristol Stool Form Scale (BSFS)</measure>
    <time_frame>Study day 1 through 14</time_frame>
    <description>Using a Daily Diary, patients recorded Stool Consistency using the 7-point Bristol Stool Form Scale (BSFS) (1 = separate hard lumps, like nuts; 2 sausage shaped but lumpy; 3 = like a sausage but with cracks on surface; 4 = like a sausage or snake, smooth and soft; 5 = soft blobs with clear-cut edges; 6 = fluffy pieces with ragged edges, a mushy stool; 7 = watery, no solid pieces, entirely liquid). Changes in mean BSFS were assessed from the average 14-day pretreatment baseline to the average during the 2-week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline Overall in Ease of Passage (Straining)</measure>
    <time_frame>Study Days 1 through 14</time_frame>
    <description>Using a Daily Diary, patients recorded Ease of Passage (Straining) using the 7-point Ease-of-Passage Scale (1 = manual disimpaction/enema needed, 2 = severe straining, 3 = moderate straining, 4 = mild straining, 5 = no straining, 6 = urgency, 7 = incontinent). Changes in overall ease of passage (Straining) were assessed from the average 14-day pretreatment baseline to average during the 2-week treatment period</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Chronic Idiopathic Constipation</condition>
  <arm_group>
    <arm_group_label>SP-304 0.3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SP-304 0.3 mg tablet by mouth once daily for 14 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SP-304 1.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SP-304 1.0 mg tablet by mouth once daily for 14 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SP-304 3.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SP-304 3.0 mg tablet by mouth once daily for 14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SP-304 9.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SP-304 9.0 mg tablet by mouth once daily for 14 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet by mouth once daily for 14 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SP-304 0.3 mg</intervention_name>
    <description>SP-304 0.3 mg</description>
    <arm_group_label>SP-304 0.3 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SP-304 1.0 mg</intervention_name>
    <description>SP-304 1.0 mg</description>
    <arm_group_label>SP-304 1.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SP-304 3.0 mg</intervention_name>
    <description>SP-304 3.0 mg</description>
    <arm_group_label>SP-304 3.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SP-304 9.0 mg</intervention_name>
    <description>SP-304 9.0 mg</description>
    <arm_group_label>SP-304 9.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is able to understand and willing to sign the Informed Consent Form (ICF) and
             capable of providing written authorization for use and disclosure of protected health
             information per requirements of 45 CFR 164.508 (Health Insurance Portability and
             Accountability Act [HIPAA]).

          -  Subject is male or non-pregnant, non-breastfeeding female, between 18 and 75 years of
             age (inclusive) at the time of first dose.

          -  Subject has a body mass index (BMI) between 18 and 35 kg/m2.

          -  Subject meets the Rome III Diagnostic Criteria for constipation (Drossman, 2006) for
             the past 3 months with symptom onset &gt; 6 months prior to diagnosis.

        Exclusion Criteria:

          -  Subject reports loose stool (fluffy pieces with ragged edges, a mushy stool) or watery
             stool (no solid pieces, entirely liquid; BSFS score of 6 or 7, respectively) in the
             absence of any laxative, enema, suppository or prohibited medicine for &gt; 25% of BMs
             during the 3 months prior to the Screening visit and during the 14 day pre-treatment
             period.

          -  Subjects who meet the Rome III criteria for IBS.

          -  Subject has failed to complete the pre-treatment bowel movement diary accurately and
             completely during the pre-treatment period prior to Day 1 dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary S Jacob, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Synergy Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novara Clinical Research</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genova Clinical Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92869</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.G.A. Clinical Trials</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Ressearch and Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lee Research Institute</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Michigan, LLC</name>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <zip>48047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtiy of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memphis Gastroenterology Group</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Medical Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCOL Center for Clinical Research</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Shailubhai K, Talluto C, Comiskey S, Foss J, Joslyn A, Jacob G. Phase II Clinical Evaluation of SP-304, a Guanylate Cyclase-C Agonist, for Treatment of Chronic Constipation. Am J Gastroenterology 105 (Supp 1): S487, 2010</citation>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2010</study_first_posted>
  <results_first_submitted>January 30, 2019</results_first_submitted>
  <results_first_submitted_qc>December 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 2, 2020</results_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Idiopathic Constipation</keyword>
  <keyword>Constipation</keyword>
  <keyword>Irritable Bowel Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plecanatide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted between 3 March 2010 and 26 August 2010 at 14 study centers in the United States. Four dose cohorts were planned (0.3 mg, 1.0 mg, 3.0 mg, and 9.0 mg with 20 patients per dose cohort randomized in a 3:1 ratio [15 pts receive SP-304, 5 pts receive placebo].</recruitment_details>
      <pre_assignment_details>During the pre-treatment period (Study Days -14 though -1), 84 eligible patients completed daily bowel movement diaries to obtain baseline data. Of these, 78 patients (58 and 20 patients for the SP-304 and placebo treatment groups, respectively) received at least one dose of study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SP-304 0.3 mg</title>
          <description>Subjects receiving SP-304 0.3 mg for 14 consecutive days.</description>
        </group>
        <group group_id="P2">
          <title>SP-304 1.0 mg</title>
          <description>Subjects receiving SP-304 1.0 mg for 14 consecutive days</description>
        </group>
        <group group_id="P3">
          <title>SP-304 3.0 mg</title>
          <description>Subjects receiving SP-304 3.0 mg for 14 consecutive days</description>
        </group>
        <group group_id="P4">
          <title>SP-304 9.0 mg</title>
          <description>Subjects receiving SP-304 9.0 mg for 14 consecutive days</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Subjects receiving Placebo for 14 consecutive days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Pretreatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrew Consent (Patient/PI)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Venipuncture Failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed Urine drug screen Day 1</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Lab values Exl 16</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population: patients who received at least one dose of study medication (population for primary endpoint).</population>
      <group_list>
        <group group_id="B1">
          <title>SP-304 1.0 mg</title>
          <description>Subjects receiving SP-304 1.0 mg for 14 consecutive days</description>
        </group>
        <group group_id="B2">
          <title>SP-304 3.0 mg</title>
          <description>Subjects receiving SP-304 3.0 mg for 14 consecutive days</description>
        </group>
        <group group_id="B3">
          <title>SP-304 9.0 mg</title>
          <description>Subjects receiving SP-304 9.0 mg for 14 consecutive days</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Subjects receiving Placebo for 14 consecutive days</description>
        </group>
        <group group_id="B5">
          <title>SP-304 0.3 mg</title>
          <description>Subjects receiving SP-304 0.3 mg for 14 consecutive days.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="20"/>
            <count group_id="B5" value="14"/>
            <count group_id="B6" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.5" spread="10.6"/>
                    <measurement group_id="B2" value="48.5" spread="16.17"/>
                    <measurement group_id="B3" value="47.3" spread="12.71"/>
                    <measurement group_id="B4" value="47.7" spread="14.64"/>
                    <measurement group_id="B5" value="51.1" spread="11.95"/>
                    <measurement group_id="B6" value="48.9" spread="13.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Complete Spontaneous Bowel Movement Frequency</title>
          <description>On daily basis during the 14-day pre-treatment period, patients recorded the number of spontaneous bowel movements having the sensation of complete evacuation (Complete Spontaneous Bowel Movement - CSBM). The Baseline Weekly Frequency of CSBMs during the pre-treatment period was calculated total number of CSBMs divided by 2 (the number of weeks in the pre-treatment period).</description>
          <units>CSBMs per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.6" spread="0.74"/>
                    <measurement group_id="B2" value="0.5" spread="0.92"/>
                    <measurement group_id="B3" value="0.4" spread="0.54"/>
                    <measurement group_id="B4" value="0.3" spread="0.53"/>
                    <measurement group_id="B5" value="0.4" spread="0.53"/>
                    <measurement group_id="B6" value="0.4" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Spontaneous Bowel Movement Frequency</title>
          <description>On daily basis during the 14-day pre-treatment period, patients recorded the number of spontaneous bowel movements (SBM). The Baseline Weekly Frequency of SBMs during the pre-treatment period was calculated total number of SBMs divided by 2 (the number of weeks in the pre-treatment period).</description>
          <units>events per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.2" spread="0.99"/>
                    <measurement group_id="B2" value="2.1" spread="0.93"/>
                    <measurement group_id="B3" value="1.9" spread="0.75"/>
                    <measurement group_id="B4" value="2.0" spread="1.01"/>
                    <measurement group_id="B5" value="2.2" spread="1.12"/>
                    <measurement group_id="B6" value="2.1" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stool Consistency (Bristol Stool Form Scale)</title>
          <description>Using a Daily Diary, patients recorded Stool Consistency using the 7-point Bristol Stool Form Scale (BSFS) (1 = separate hard lumps, like nuts; 2 sausage shaped but lumpy; 3 = like a sausage but with cracks on surface; 4 = like a sausage or snake, smooth and soft; 5 = soft blobs with clear-cut edges; 6 = fluffy pieces with ragged edges, a mushy stool; 7 = watery, no solid pieces, entirely liquid).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.6" spread="0.84"/>
                    <measurement group_id="B2" value="1.8" spread="0.69"/>
                    <measurement group_id="B3" value="2.7" spread="1.56"/>
                    <measurement group_id="B4" value="2.6" spread="1.28"/>
                    <measurement group_id="B5" value="2.5" spread="0.81"/>
                    <measurement group_id="B6" value="2.4" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ease of Passage (Straining)</title>
          <description>Using a Daily Diary, patients recorded Ease of Passage (Straining) using the 7-point Ease-of-Passage Scale (1 = manual disimpaction/enema needed, 2 = severe straining, 3 = moderate straining, 4 = mild straining, 5 = no straining, 6 = urgency, 7 = incontinent).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.8" spread="0.79"/>
                    <measurement group_id="B2" value="2.7" spread="0.61"/>
                    <measurement group_id="B3" value="3.0" spread="0.89"/>
                    <measurement group_id="B4" value="3.0" spread="0.67"/>
                    <measurement group_id="B5" value="3.1" spread="0.64"/>
                    <measurement group_id="B6" value="2.9" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Incidences of adverse events from Baseline through the end of the Follow-up period.</description>
        <time_frame>21 days: Baseline through Follow-up (Treatment Days 14, 7 days post treatment)</time_frame>
        <population>Safety Population: all patients who received at least one dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>SP-304 0.3 mg</title>
            <description>Subjects receiving SP-304 0.3 mg for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>SP-304 1.0 mg</title>
            <description>Subjects receiving SP-304 1.0 mg for 14 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>SP-304 3.0 mg</title>
            <description>Subjects receiving SP-304 3.0 mg for 14 consecutive days</description>
          </group>
          <group group_id="O4">
            <title>SP-304 9.0 mg</title>
            <description>Subjects receiving SP-304 9.0 mg for 14 consecutive days</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Subjects receiving Placebo for 14 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Incidences of adverse events from Baseline through the end of the Follow-up period.</description>
          <population>Safety Population: all patients who received at least one dose of the study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Overall in Number of Complete Spontaneous Bowel Movements (CSBM)</title>
        <description>Using a Daily Diary, patients recorded the number of spontaneous bowel movements having the sensation of complete evacuation (Complete Spontaneous Bowel Movement - CSBM). The total number of spontaneous bowel movements associated with a feeling of complete evacuation were summed and divided by 2 (the number of weeks in treatment). Change was calculated as the difference between the number of the CSBMs at the completion of the 2-week treatment period, versus the 14-day pretreatment baseline.</description>
        <time_frame>Study days 1 through 14</time_frame>
        <population>Modified-Intent-to-Treat population: All patients who received at least one dose of study medication and had at least one post-baseline diary assessment. One participant in the SP-304 0.3 mg group did not have information about complete evacuation post-baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>SP-304 0.3 mg</title>
            <description>Subjects receiving SP-304 0.3 mg for 14 consecutive days.
SP-304 0.3 mg: Subjects receiving SP-304 0.3 mg for 14 consecutive</description>
          </group>
          <group group_id="O2">
            <title>SP-304 1.0 mg</title>
            <description>Subjects receiving SP-304 1.0 mg for 14 consecutive days
SP-304: Subjects receiving SP-304 1.0 mg for 14 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>SP-304 3.0 mg</title>
            <description>Subjects receiving SP-304 3.0 mg for 14 consecutive days
SP-304: Subjects receiving SP-304 3.0 mg for 14 consecutive days</description>
          </group>
          <group group_id="O4">
            <title>SP-304 9.0 mg</title>
            <description>Subjects receiving SP-304 9.0 mg for 14 consecutive days
SP-304: Subjects receiving SP-304 9.0 mg for 14 consecutive days</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Subjects receiving Placebo for 14 consecutive days
Placebo: Subjects receiving Placebo for 14 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Overall in Number of Complete Spontaneous Bowel Movements (CSBM)</title>
          <description>Using a Daily Diary, patients recorded the number of spontaneous bowel movements having the sensation of complete evacuation (Complete Spontaneous Bowel Movement - CSBM). The total number of spontaneous bowel movements associated with a feeling of complete evacuation were summed and divided by 2 (the number of weeks in treatment). Change was calculated as the difference between the number of the CSBMs at the completion of the 2-week treatment period, versus the 14-day pretreatment baseline.</description>
          <population>Modified-Intent-to-Treat population: All patients who received at least one dose of study medication and had at least one post-baseline diary assessment. One participant in the SP-304 0.3 mg group did not have information about complete evacuation post-baseline.</population>
          <units>CSBMs per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="2.30"/>
                    <measurement group_id="O2" value="3.3" spread="2.85"/>
                    <measurement group_id="O3" value="1.8" spread="3.75"/>
                    <measurement group_id="O4" value="2.7" spread="2.89"/>
                    <measurement group_id="O5" value="2.0" spread="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Overall in Number of Spontaneous Bowel Movements (SBM)</title>
        <description>Using a Daily Diary, patients recorded the number of spontaneous bowel movements (SBM). The overall weekly frequency was calculated as the total number of SBMs divided by 2 (the number weeks of treatment). Change was calculated as the difference between the number of the SBMs at the completion of the 2-week treatment period, versus the 14-day pretreatment baseline.</description>
        <time_frame>Study Days 1 through 14</time_frame>
        <population>Modified-Intent-to-Treat population: All patients who received at least one dose of study medication and had at least one post-baseline diary assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>SP-304 0.3 mg</title>
            <description>Subjects receiving SP-304 0.3 mg for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>SP-304 1.0 mg</title>
            <description>Subjects receiving SP-304 1.0 mg for 14 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>SP-304 3.0 mg</title>
            <description>Subjects receiving SP-304 3.0 mg for 14 consecutive days</description>
          </group>
          <group group_id="O4">
            <title>SP-304 9.0 mg</title>
            <description>Subjects receiving SP-304 9.0 mg for 14 consecutive days</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Subjects receiving Placebo for 14 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Overall in Number of Spontaneous Bowel Movements (SBM)</title>
          <description>Using a Daily Diary, patients recorded the number of spontaneous bowel movements (SBM). The overall weekly frequency was calculated as the total number of SBMs divided by 2 (the number weeks of treatment). Change was calculated as the difference between the number of the SBMs at the completion of the 2-week treatment period, versus the 14-day pretreatment baseline.</description>
          <population>Modified-Intent-to-Treat population: All patients who received at least one dose of study medication and had at least one post-baseline diary assessment.</population>
          <units>SBMs per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="2.21"/>
                    <measurement group_id="O2" value="4.1" spread="4.1"/>
                    <measurement group_id="O3" value="2.4" spread="3.39"/>
                    <measurement group_id="O4" value="4.2" spread="2.88"/>
                    <measurement group_id="O5" value="2.4" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline Overall in Bristol Stool Form Scale (BSFS)</title>
        <description>Using a Daily Diary, patients recorded Stool Consistency using the 7-point Bristol Stool Form Scale (BSFS) (1 = separate hard lumps, like nuts; 2 sausage shaped but lumpy; 3 = like a sausage but with cracks on surface; 4 = like a sausage or snake, smooth and soft; 5 = soft blobs with clear-cut edges; 6 = fluffy pieces with ragged edges, a mushy stool; 7 = watery, no solid pieces, entirely liquid). Changes in mean BSFS were assessed from the average 14-day pretreatment baseline to the average during the 2-week treatment period.</description>
        <time_frame>Study day 1 through 14</time_frame>
        <population>Modified-Intent-to-Treat population: All patients who received at least one dose of study medication and had at least one post-baseline diary assessment. One participant in the SP-304 0.3 mg group did not have post-baseline results.</population>
        <group_list>
          <group group_id="O1">
            <title>SP-304 0.3 mg</title>
            <description>Subjects receiving SP-304 0.3 mg for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>SP-304 1.0 mg</title>
            <description>Subjects receiving SP-304 1.0 mg for 14 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>SP-304 3.0 mg</title>
            <description>Subjects receiving SP-304 3.0 mg for 14 consecutive days</description>
          </group>
          <group group_id="O4">
            <title>SP-304 9.0 mg</title>
            <description>Subjects receiving SP-304 9.0 mg for 14 consecutive days</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Subjects receiving Placebo for 14 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline Overall in Bristol Stool Form Scale (BSFS)</title>
          <description>Using a Daily Diary, patients recorded Stool Consistency using the 7-point Bristol Stool Form Scale (BSFS) (1 = separate hard lumps, like nuts; 2 sausage shaped but lumpy; 3 = like a sausage but with cracks on surface; 4 = like a sausage or snake, smooth and soft; 5 = soft blobs with clear-cut edges; 6 = fluffy pieces with ragged edges, a mushy stool; 7 = watery, no solid pieces, entirely liquid). Changes in mean BSFS were assessed from the average 14-day pretreatment baseline to the average during the 2-week treatment period.</description>
          <population>Modified-Intent-to-Treat population: All patients who received at least one dose of study medication and had at least one post-baseline diary assessment. One participant in the SP-304 0.3 mg group did not have post-baseline results.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.23"/>
                    <measurement group_id="O2" value="1.8" spread="1.18"/>
                    <measurement group_id="O3" value="1.6" spread="1.53"/>
                    <measurement group_id="O4" value="1.8" spread="1.56"/>
                    <measurement group_id="O5" value="0.9" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline Overall in Ease of Passage (Straining)</title>
        <description>Using a Daily Diary, patients recorded Ease of Passage (Straining) using the 7-point Ease-of-Passage Scale (1 = manual disimpaction/enema needed, 2 = severe straining, 3 = moderate straining, 4 = mild straining, 5 = no straining, 6 = urgency, 7 = incontinent). Changes in overall ease of passage (Straining) were assessed from the average 14-day pretreatment baseline to average during the 2-week treatment period</description>
        <time_frame>Study Days 1 through 14</time_frame>
        <population>Modified-Intent-to-Treat population: All patients who received at least one dose of study medication and had at least one post-baseline diary assessment. One participant in the SP-304 0.3 mg group did not have post-baseline results.</population>
        <group_list>
          <group group_id="O1">
            <title>SP-304 0.3 mg</title>
            <description>Subjects receiving SP-304 0.3 mg for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>SP-304 1.0 mg</title>
            <description>Subjects receiving SP-304 1.0 mg for 14 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>SP-304 3.0 mg</title>
            <description>Subjects receiving SP-304 3.0 mg for 14 consecutive days</description>
          </group>
          <group group_id="O4">
            <title>SP-304 9.0 mg</title>
            <description>Subjects receiving SP-304 9.0 mg for 14 consecutive days</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Subjects receiving Placebo for 14 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline Overall in Ease of Passage (Straining)</title>
          <description>Using a Daily Diary, patients recorded Ease of Passage (Straining) using the 7-point Ease-of-Passage Scale (1 = manual disimpaction/enema needed, 2 = severe straining, 3 = moderate straining, 4 = mild straining, 5 = no straining, 6 = urgency, 7 = incontinent). Changes in overall ease of passage (Straining) were assessed from the average 14-day pretreatment baseline to average during the 2-week treatment period</description>
          <population>Modified-Intent-to-Treat population: All patients who received at least one dose of study medication and had at least one post-baseline diary assessment. One participant in the SP-304 0.3 mg group did not have post-baseline results.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.05"/>
                    <measurement group_id="O2" value="1.6" spread="1.04"/>
                    <measurement group_id="O3" value="1.3" spread="1.17"/>
                    <measurement group_id="O4" value="1.2" spread="1.06"/>
                    <measurement group_id="O5" value="0.5" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>21 Days</time_frame>
      <desc>Baseline through 14 consecutive days of treatment plus 7 post-treatment days</desc>
      <group_list>
        <group group_id="E1">
          <title>SP-304 0.3 mg</title>
          <description>Subjects receiving SP-304 0.3 mg for 14 consecutive days.</description>
        </group>
        <group group_id="E2">
          <title>SP-304 1.0 mg</title>
          <description>Subjects receiving SP-304 1.0 mg for 14 consecutive days</description>
        </group>
        <group group_id="E3">
          <title>SP-304 3.0 mg</title>
          <description>Subjects receiving SP-304 3.0 mg for 14 consecutive days</description>
        </group>
        <group group_id="E4">
          <title>SP-304 9.0 mg</title>
          <description>Subjects receiving SP-304 9.0 mg for 14 consecutive days</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Subjects receiving Placebo for 14 consecutive days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hiatus Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tingling Feeling in Mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Upset Stomach</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal Cramping</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Excessive Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Tiredness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis (Due To Pollen)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Low Back Strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated Amylase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Elevated Lipase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Intermittent Right Hand Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>One Episode of Neck Muscle Spasm Left Side</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Head Pressure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Intermittent Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the results, either in part or in total (e.g., articles in journals or newspapers, oral presentations, abstracts) by the Investigator(s) or their representative(s), shall require prior notification, review, within a reasonable time frame, and written approval by the Sponsor. Additionally such publications cannot be made in violation of the Sponsors confidentiality restrictions or to the detriment of the Sponsors intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This Phase 2a study was not sized to evaluate efficacy.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Laura Barrow/Senior Vice President Clinical Development</name_or_title>
      <organization>Synergy Pharmaceuticals Inc</organization>
      <phone>212-297-0020</phone>
      <email>lbarrow@synergypharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

